CellaVision
242.5
SEK
+0.21 %
CEVI
NASDAQ Stockholm
Medical Equipment & Services
Health Care
1,502 following
ir.cellavision.com
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Revenue
677.29M
EBIT %
24.66 %
P/E
44.41
Dividend yield-%
0.93 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CEVI
Daily low / high price
235 / 245.5
SEK
Market cap
5.78B SEK
Turnover
4.65M SEK
Volume
19K
Latest videos
Financial calendar
Annual report
2025-02-06
Interim report
2025-04-29
General meeting
2025-05-06
Interim report
2025-07-18
Interim report
2025-11-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 19.9 % | 19.9 % |
Grenlunden CEVI AB | 10.0 % | 10.0 % |
SEB Fonder | 9.2 % | 9.2 % |
Christer Fåhraeus o bol | 6.8 % | 6.8 % |
Swedbank Robur fonder | 5.4 % | 5.4 % |
Invesco | 3.8 % | 3.8 % |
Fjärde AP-fonden | 3.0 % | 3.0 % |
Handelsbanken Fonder | 2.9 % | 2.9 % |
La Financière de l'Echiquier | 2.6 % | 2.6 % |
AMF Pension & Fonder | 2.5 % | 2.5 % |
ShowingAll content types
Nomination Committee for the CellaVision Annual General Meeting 2025
Redeye: Cellavision Q3’2024 - Underlying momentum intact
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools